Mirum Pharmaceuticals Reports Q1 2026 Earnings and Financial Performance
Mirum Pharmaceuticals (MIRM) reported Q1 2026 earnings with total net product sales of $160 million, up from $112 million in the same quarter the previous year. The company raised its full-year 2026 net product sales guidance to $660 million to $680 million. Key financial highlights include a cash contribution margin in the mid-50% range and a net cash outlay of $253 million for the Bluejay Therapeutics acquisition.
Tickers: $MIRM
Topics: acquisition cash_flow financial_results guidance sales